Table 4 Characteristics at baseline according to treatment group in the overall population and when three matching calipers were used

Sex^a

4%

1%

2%

0.8%

  Female

1451 (73%)

2247 (71%)

1175 (72%)

1167 (72%)

1183 (72%)

1169 (71%)

1169 (72%)

1163 (28%)

  Male

538 (27%)

912 (29%)

454 (28%)

462 (28%)

456 (28%)

470 (29%)

447 (28%)

453 (28%)

Age at treatment start^b

MS duration at treatment^b

36.6 (29.3; 43.9)

6.3 (2.4; 11.8)

38.5 (31.6; 45.4)

7.4 (3.6; 13.0)

13%

13%

37.2 (29.8–44.4)

6.3 (2.3–12.2)

37.4 (30.3–44.2)

6.5 (2.9–11.8)

0.5%

2%

37.2 (29.7–44.4)

6.2 (2.3–12.2)

37.4 (30.3–44.3)

6.6 (2.9–11.9)

1%

2%

37.3 (29.7–44.4)

6.3 (2.3–12.2)

37.6 (30.5–44.5)

6.4 (2.8–11.9)

3%

2%

EDSS at treatment start^a

32%

5%

9%

7%

  2 or less

434 (22%)

1122 (35%)

374 (23%)

408 (25%)

377 (23%)

433 (26%)

372 (23%)

417(26%)

  Between 2 and 4

981 (49%)

1403 (44%)

822 (50%)

787 (48%)

826 (50%)

767 (47%)

813 (50%)

775 (48%)

  4 or more

574 (29%)

634 (20%)

433 (27%)

434 (27%)

436 (25%)

439 (27%)

431 (27%)

424 (26%)

Number of relapses in the previous 12 months^a

37%

8%

6%

6%

  0

570 (29%)

1287 (41%)

543 (33%)

520 (32%)

545 (33%)

540 (33%)

541 (33%)

518 (32%)

  1

752 (38%)

1269 (40%)

620 (38%)

670 (41%)

623 (38%)

645 (39%)

618 (38%)

658 (41%)

  2

484 (24%)

491 (15%)

346 (21%)

344 (21%)

351 (22%)

356 (22%)

350 (22%)

346 (21%)

  3 or more

183 (9%)

112 (3%)

120 (7%)

95 (6%)

120 (7%)

98 (6%)

107 (7%)

94 (6%)

Number of previous MS treatments^a

17%

17%

17%

16%

  0

401 (20%)

435 (14%)

334 (21%)

248 (15%)

337 (21%)

243 (15%)

334 (21%)

250 (15%)

  1

924 (46%)

1635 (52%)

742 (46%)

852 (52%)

746 (46%)

851 (52%)

732 (4%)

826 (51%)

  2

457 (23%)

730 (23%)

367 (23%)

371 (23%)

370 (23%)

374 (23%)

365 (23%)

383 (24%)

  3 or more

207 (10%)

359 (11%)

186 (11%)

158 (10%)

186 (11%)

171 (10%)

185 (11%)

157 (10%)

MS activity in the previous 12 months^a

29%

4%

2%

3%

  None

410 (21%)

1028 (32%)

393 (24%)

383 (24%)

395 (24%)

387 (24%)

390 (24%)

374 (23%)

  Worsening

160 (8%)

259 (8%)

150 (9%)

137 (8%)

150 (9%)

153 (9%)

151(9%)

144 (9%)

  Relapse

886 (44%)

1273 (40%)

686 (42%)

709 (44%)

694 (42%)

704 (43%)

690 (43%)

707 (44%)

  Relapse and worsening

533 (27%)

599 (19%)

400 (25%)

400 (25%)

400 (24%)

395 (24%)

385 (24%)

391 (24%)

Data source^a

28%

18%

16%

12%

  MS Base

1141 (57%)

2152 (68%)

949 (58%)

925 (57%)

957 (58%)

925 (56%)

935 (58%)

917 (57%)

  DMSR

607 (31%)

837 (26%)

607 (37%)

560 (34%)

607 (37%)

572 (35%)

593 (37%)

560 (35%)

  OFSEP

241 (12%)

170 (5%)

73 (4%)

144 (9%)

75 (5%)

142 (9%)

88 (5%)

139 (9%)